Stockreport

Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Palvella Therapeutics, Inc.  (PVLA) 
PDF Palvella’s recently expanded rare disease pipeline now comprises QTORIN™-derived product candidates advancing in four serious, rare skin diseases that currently have no [Read more]